Targeting oncogenic pathways: A new era in cancer treatment.

Marcello Giorgi*

Department of Surgery, Duke University, USA

Introduction

Cancer remains one of the leading causes of death worldwide, with millions of lives affected every year. The traditional approaches to cancer treatment, including surgery, chemotherapy, and radiotherapy, have been pivotal in managing the disease. However, these treatments are not always effective and often come with significant side effects. In recent years, the landscape of cancer treatment has been revolutionized with the emergence of targeted therapies. These therapies aim to disrupt specific molecular pathways involved in cancer cell growth and survival, offering a more precise and potentially less toxic alternative to traditional treatments [1].

Oncogenic pathways are a series of cellular processes that promote cancer cell growth, survival, and metastasis. These pathways are often triggered by mutations in key genes that regulate normal cell function. The mutations can lead to uncontrolled cell division, resistance to cell death, and the ability to invade surrounding tissues. Some of the most well-known oncogenic pathways include the PI3K/Akt/mTOR pathway, the RAS/MAPK pathway, and the Wnt/β-catenin pathway, each of which plays a pivotal role in various cancers [2].

The key to targeting these pathways lies in understanding the molecular mechanisms that drive cancer progression. By pinpointing specific molecular targets within these pathways, researchers can design drugs that selectively interfere with the abnormal signaling driving tumor growth, rather than affecting healthy cells. This approach minimizes the collateral damage associated with conventional therapies [3].

Targeted therapies are designed to block the activity of specific molecules involved in the growth and spread of cancer. One of the most significant advancements in targeted cancer therapy is the development of small molecule inhibitors and monoclonal antibodies. Small molecule inhibitors are compounds that interfere with the function of specific proteins within the oncogenic pathway, while monoclonal antibodies bind to these proteins, preventing them from signaling cancer cells to grow and divide [4].

One of the earliest success stories in targeted therapy was the development of imatinib (Gleevec), a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein in chronic myelogenous leukemia (CML). This was a groundbreaking achievement, as it specifically targeted the genetic mutation driving CML without affecting normal cells. Following this success, targeted therapies have been developed for a variety of cancers, including breast cancer (HER2 inhibitors), lung cancer (EGFR inhibitors), and melanoma (BRAF inhibitors) [5].

The PI3K/Akt/mTOR pathway is one of the most commonly dysregulated pathways in cancer. It plays a crucial role in cell metabolism, growth, and survival. Mutations in genes within this pathway, such as PIK3CA (which encodes for the p110α catalytic subunit of PI3K), can lead to excessive activation, resulting in uncontrolled cancer cell proliferation. Targeting this pathway with inhibitors, such as everolimus (a mTOR inhibitor), has shown promise in treating cancers like breast cancer and renal cell carcinoma. However, resistance to these drugs is an ongoing challenge, underscoring the need for combination therapies [6].

The RAS/MAPK pathway is another critical pathway involved in cancer progression, especially in cancers like pancreatic, lung, and colon cancer. Mutations in the KRAS gene, which encodes a key protein in this pathway, are present in a significant percentage of cancers, contributing to the transformation of normal cells into cancerous ones. Historically, targeting the RAS/MAPK pathway has been challenging due to the difficulty of directly inhibiting the RAS protein. However, recent advancements in drug development, such as the approval of sotorasib (a KRAS G12C inhibitor), offer new hope for treating tumors harboring specific KRAS mutations [7].

The Wnt/β-catenin pathway plays a critical role in embryonic development, but its aberrant activation is associated with various cancers, including colorectal cancer. In normal cells, the Wnt pathway is tightly regulated, but mutations in the pathway can lead to the accumulation of β-catenin in the cytoplasm, which translocates to the nucleus and promotes the transcription of genes involved in cell proliferation and survival. Targeting the Wnt/β-catenin pathway has proven difficult due to the complexity of its regulation, but ongoing research into small molecules that inhibit this pathway holds promise for future therapeutic strategies [8].

While targeting oncogenic pathways has provided significant advances in cancer treatment, resistance to these therapies remains a major hurdle. Cancer cells can develop resistance through various mechanisms, such as the activation of alternative signaling pathways, mutations in the drug target, or increased drug efflux. To overcome resistance, researchers are exploring combination therapies that target multiple pathways

***Correspondence to:** Marcello Giorgi**,** Department of Surgery, Duke University, USA. E-mail: marcello.giorgi@duke.edu

***Received:** 1-Jan-2024, Manuscript No. JMOT-25-157411; **Editor assigned:** 4-Jan-2024, PreQC No. JMOT-25-157411 (PQ); **Reviewed:** 17-Jan-2024, QC No. JMOT-25-157411; **Revised:** 24-Jan-2024, Manuscript No. JMOT-25-157411 (R); **Published:** 31-Jan-2024, DOI: 10.35841/jmot-10.1.248*

***Citation:** Giorgi M. Targeting oncogenic pathways: A new era in cancer treatment. J Med Oncl Ther. 2025;10(1):248.*

simultaneously. For example, combining PI3K inhibitors with immunotherapy or chemotherapy may help overcome resistance and improve treatment outcomes [9].

The development of targeted therapies has paved the way for b, where treatment is tailored to the specific genetic makeup of a patient's tumor. Advances in genomic sequencing have allowed oncologists to identify the mutations driving individual cancers, enabling more precise targeting of therapeutic interventions. By analyzing the genetic profile of tumors, doctors can select the most appropriate targeted therapies for each patient, improving the chances of success and minimizing unnecessary treatments [10].

Conclusion

The era of targeting oncogenic pathways marks a transformative shift in cancer treatment, offering a more precise and effective approach compared to traditional therapies. While challenges remain, the continuous development of targeted therapies, coupled with advances in genomic sequencing and personalized medicine, promises to improve treatment outcomes and provide new hope for patients worldwide. As research progresses, the potential for curing cancers that were once deemed intractable becomes more tangible, bringing us closer to a future where cancer is no longer a death sentence but a manageable condition.

References

1. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34.
2. Karagiannakos A, Adamaki M, Tsintarakis A, et al. Targeting oncogenic pathways in the era of personalized oncology: A systemic analysis reveals highly mutated signaling pathways in cancer patients and potential therapeutic targets. Cancers. 2022;14(3):664.
3. Basu S, Chaudhuri P, Sengupta S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle. 2009;8(21):3480-7.
4. Zhu G, Saboor-Yaraghi AA, Yarden Y. Targeting oncogenic receptor: From molecular physiology to currently the standard of target therapy. Adv Pharm J. 2017;2(1):10-28.
5. Voltz E, Gronemeyer H. A new era of cancer therapy: Cancer cell targeted therapies are coming of age. Int J Biochem Cell Biol. 2008;40(1):1-8.
6. Willis RE. Targeted cancer therapy: Vital oncogenes and a new molecular genetic paradigm for cancer initiation progression and treatment. Int J Mol Sci. 2016;17(9):1552.
7. Santarpia L, Bottai G, Kelly CM, et al. Deciphering and targeting oncogenic mutations and pathways in breast cancer. The oncologist. 2016;21(9):1063-78.
8. Sharma V, Kushwaha V, Panwar A, et al. Oncogenes and oncogenesis: Origin, development, cause, and therapy. Anticancer Ther. 2024:31.
9. Ko JM, Fisher DE. A new era: Melanoma genetics and therapeutics. J Pathol. 2011;223(2):242-51.
10. Ferrara MG, Di Noia V, D'Argento E, et al. Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives. Cancers. 2020;12(5):1196.

Citation: *Giorgi M. Targeting oncogenic pathways: A new era in cancer treatment. J Med Oncl Ther. 2025;10(1):248.*